豚草花粉中的一种新半胱氨酸蛋白酶过敏原:前体和成熟形式。
A new cysteine protease allergen from Ambrosia trifida pollen: proforms and mature forms.
机构信息
Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China; Department of Clinical Pharmacy, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
出版信息
Mol Immunol. 2022 Jul;147:170-179. doi: 10.1016/j.molimm.2022.05.003. Epub 2022 May 19.
Giant ragweed (Ambrosia trifida) pollen is closely associated with respiratory allergy in late summer and autumn, and the prevalence of giant ragweed pollen allergy progressively increases. Compared with short ragweed (Ambrosia artemisiifolia), allergenic components from giant ragweed pollen are poorly investigated. To promote component-resolved diagnosis and treatment for giant ragweed pollen allergy, it becomes necessary to identify and characterize unknown allergens from giant ragweed pollen. In the present study, we identified and characterized a new cysteine-protease (CP) allergen from giant ragweed pollen, named as Amb t CP. The cloned Amb t CP gene encoded 387 amino acids. Recombinant Amb t CP (rAmb t CP) and natural Amb t CP (nAmb t CP) were purified by high-affinity Ni resin and immunoaffinity chromatography respectively. During refolding, purified rAmb t CP could autocatalytically converted to its mature forms displaying a higher enzymatic activity. Moreover, the autocatalytic conversion of proforms to mature forms of nAmb t CP could cause their amount to change in giant ragweed pollen extracts. Then, the allergenicity of Amb t CP was characterized: 23 (33.8%) of 68 Chinese patients with ragweed pollen allergy showed positive IgE binding to nAmb t CP by enzyme-linked immunosorbent assay (ELISA); the result of subsequent ELISA showed that IgE-binding activity of proforms and mature forms of rAmb t CP was different, with positive rate of 39.1% (9/23) and 47.8% (11/23) respectively; Amb t CP showed IgE cross-reactivity with the CP components from short ragweed, Artemisia annua and Artemisia sieversiana pollen. Our findings will help to promote component-resolved diagnosis and treatment for giant ragweed pollen allergy, standardize allergen products and individualize allergen-specific immunotherapy.
豚草花粉与夏末和秋季的呼吸道过敏密切相关,豚草花粉过敏的患病率逐渐增加。与短豚草(Ambrosia artemisiifolia)相比,豚草花粉中的变应原成分研究甚少。为了促进豚草花粉过敏的成分分辨诊断和治疗,有必要从豚草花粉中鉴定和表征未知的变应原。在本研究中,我们从豚草花粉中鉴定和表征了一种新的半胱氨酸蛋白酶(CP)变应原,命名为 Amb t CP。克隆的 Amb t CP 基因编码 387 个氨基酸。通过高亲和力 Ni 树脂和免疫亲和层析分别纯化重组 Amb t CP(rAmb t CP)和天然 Amb t CP(nAmb t CP)。在复性过程中,纯化的 rAmb t CP 可以自动催化转化为具有更高酶活性的成熟形式。此外,nAmb t CP 前体形式向成熟形式的自动催化转化会导致其在豚草花粉提取物中的含量发生变化。然后,表征了 Amb t CP 的变应原性:68 例中国豚草花粉过敏患者中,有 23 例(33.8%)通过酶联免疫吸附试验(ELISA)显示对 nAmb t CP 有阳性 IgE 结合;随后的 ELISA 结果表明,rAmb t CP 前体和成熟形式的 IgE 结合活性不同,阳性率分别为 39.1%(9/23)和 47.8%(11/23);Amb t CP 与短豚草、青蒿和艾蒿花粉中的 CP 成分具有 IgE 交叉反应性。我们的研究结果将有助于促进豚草花粉过敏的成分分辨诊断和治疗,规范变应原产品,实现变应原特异性免疫治疗的个体化。